secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2024-08-21T23:59:59+00:00
Accession:  0001493152-24-033383
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics completes spray-dry manufacturing of ONP-002 for Phase IIa concussion trial
--------------------------------------------------------------------------------

- ONP-002 produced as spray-dried nanoparticle powder and filled in Oragenics' breath-propelled intranasal device.
- Phase IIa trial to enroll 40 concussed patients (1:1 placebo/ONP-002), dosed twice daily for 5 days starting within 8 hours of injury in ED.
- Trial will be conducted in Australia; patient-reported outcomes and blood biomarkers included in evaluation.
- No approved pharmaceutical treatment for concussion; ONP-002 is a novel neurosteroid designed as first-in-class therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224033383/0001493152-24-033383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224033383/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-033383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer